Funding Information Takeda Science Foundation.
Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma
Article first published online: 20 MAY 2014
© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Volume 105, Issue 7, pages 883–889, July 2014
How to Cite
Cancer Sci (2014) 883–889
- Issue published online: 14 JUL 2014
- Article first published online: 20 MAY 2014
- Accepted manuscript online: 23 APR 2014 05:05AM EST
- Manuscript Accepted: 18 APR 2014
- Manuscript Revised: 7 APR 2014
- Manuscript Received: 23 JAN 2014
- Takeda Science Foundation
- Bcl-2 family;
- malignant pleural mesothelioma;
- synthetic anticancer compound
The newly synthesized naftopidil analogue HUHS1015 reduced cell viability in malignant pleural mesothelioma cell lines MSTO-211H, NCI-H28, NCI-H2052, and NCI-H2452, with the potential greater than that for the anticancer drugs paclitaxel or cisplatin at concentrations higher than 30 μM. HUHS1015 induced both necrosis and apoptosis of MSTO-211H and NCI-H2052 cells. HUHS1015 upregulated expression of mRNAs for Puma, Hrk, and Noxa in MSTO-211H and NCI-H2052 cells, suggesting HUHS1015-induced mitochondrial apoptosis. HUHS1015 clearly suppressed tumor growth in mice inoculated with NCI-H2052 cells. Taken together, the results of the present study indicate that HUHS1015 could be developed as an effective anticancer drug for treatment of malignant pleural mesothelioma.